PTC Therapeutics Inc. (PTCT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
PTC Therapeutics Inc. (PTCT) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (41% profit margin, 85% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
How PTCT Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $1.73B | 44% | 50.1% | $683.0M | $702.3M | 95% |
| FY 2024 | $806.8M | 44% | -37.5% | -$363.3M | -$114.2M | -45% |
| FY 2023 | $937.8M | 44% | -46.9% | -$626.6M | -$200.6M | -19.4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring PTCT)
- ✓Live walkthrough of PTCT's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
PTCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +114.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PTCT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PTCT. Explore sector supply chains on /butterfly.
PTCT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is PTC Therapeutics Inc. (PTCT)?
In FY 2025 (10-K), PTCT converted $1.7B of revenue into a 44% gross margin, 44% operating margin, and $702.3M in free cash flow (40.6% FCF margin).